UK Reports 216 Suspected Deaths Linked to GLP-1 Drugs

The Story in Brief

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has received 216 reports of suspected deaths involving GLP-1 drugs, according to data from its Yellow Card scheme. The reports include 120 deaths linked to tirzepatide (Mounjaro), 59 to semaglutide (Wegovy, Ozempic, Rybelsus), and 37 to liraglutide (Saxenda). However, the MHRA stresses that a suspected adverse drug reaction is not the same as a confirmed medication-related death. The Yellow Card system is an early-warning mechanism; doctors and patients report suspicions, not proven causality.

Experts caution that the figures must be seen in context. Many patients on these drugs already have conditions like diabetes or heart disease that raise their risk of death independently. Large clinical trials have shown significant benefits, including reduced cardiovascular events. The MHRA maintains that the benefits outweigh the risks when the medicines are used appropriately. The issue resonates in India, where GLP-1 drugs are increasingly popular for diabetes and weight loss, prompting concerns over self-medication, counterfeits, and inadequate monitoring.